Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. 1992

A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
Department of Medicine, Medical College of Wisconsin, Milwaukee 53226.

Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) has a poor prognosis when treated with conventional chemotherapy. We analyzed the outcome of 67 HLA-identical sibling bone marrow transplants (BMTs) for Ph1-positive ALL reported to the International Bone Marrow Transplant Registry (IBMTR). Twenty-one of 67 (31%) transplant recipients survived in continuous complete remission more than 2 years after transplant. Two-year actuarial probabilities (95% confidence interval) of leukemia-free survival were 38% (23% to 55%) for 33 patients transplanted in first remission, 41% (23% to 61%) for 22 patients transplanted after relapse, and 25% (9% to 53%) for 12 patients failing to achieve remission with conventional chemotherapy. These data indicate that transplants are effective treatment for Ph1-positive ALL.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010677 Philadelphia Chromosome An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE). Ph1 Chromosome,Ph 1 Chromosome,1 Chromosomes, Ph,Chromosome, Ph 1,Chromosome, Ph1,Chromosome, Philadelphia,Chromosomes, Ph 1,Chromosomes, Ph1,Ph 1 Chromosomes,Ph1 Chromosomes
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
November 1995, Bone marrow transplantation,
A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
March 1996, Bone marrow transplantation,
A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
January 1986, Leukemia research,
A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
August 1987, Blood,
A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
August 1991, [Rinsho ketsueki] The Japanese journal of clinical hematology,
A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
December 1998, Bone marrow transplantation,
A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
January 2004, Bone marrow transplantation,
A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
May 1989, [Rinsho ketsueki] The Japanese journal of clinical hematology,
A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
April 1994, Pathology,
A J Barrett, and M M Horowitz, and R C Ash, and K Atkinson, and R P Gale, and J M Goldman, and P J Henslee-Downey, and R H Herzig, and B Speck, and F E Zwaan
December 2015, Hematology (Amsterdam, Netherlands),
Copied contents to your clipboard!